Evidence map›Paper›PMID 30635820›Full record

ArticleMolecular and cellular biochemistry2019

LncRNA ZEB2-AS1 contributes to the tumorigenesis of gastric cancer via activating the Wnt/β-catenin pathway.

Feixia Wang, Wu Zhu, Ruili Yang, Wanhua Xie, Daojun Wang

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular and cellular biochemistry, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
3.8field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 63 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. TheAnnals of translational medicine · 2022
    Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. The Hypoxia-Long Noncoding RNA Interaction in Solid Cancers.International journal of molecular sciences · 2021
    Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Feixia WangDepartment of Clinical Laboratory, Chang'an Hospital, Xi'an, 710016, Shaanxi, People's Republic of China.
Wu ZhuDepartment of Clinical Laboratory, Ankang Municipality of Traditional Chinese Medicine Hospital, No. 47, East Bashan Road, Ankang, 725000, Shaanxi, People's Republic of China.
Ruili YangDepartment of Clinical Laboratory, Chang'an Hospital, Xi'an, 710016, Shaanxi, People's Republic of China.
Wanhua XieDepartment of Clinical Laboratory, Ankang Municipality of Traditional Chinese Medicine Hospital, No. 47, East Bashan Road, Ankang, 725000, Shaanxi, People's Republic of China.
Daojun WangDepartment of Clinical Laboratory, Ankang Municipality of Traditional Chinese Medicine Hospital, No. 47, East Bashan Road, Ankang, 725000, Shaanxi, People's Republic of China. daojunwangdj@126.com.
Ankang City Central Hospital · CN

Funding

Si miao Plan of Shaanxi Provincial Natural Science Foundation No. 2016ZDKF19
6 · The paper itself

Abstract

Studies have shown that long noncoding RNA Zinc finger E-box-binding homeobox 2 antisense RNA 1 (ZEB2-AS1) is involved in the progression of lung cancer, bladder cancer, and hepatocellular carcinoma. However, its role in the pathogenesis of gastric cancer remains unknown. The Wnt/β-catenin pathway contributes to the development of gastric cancer. ZEB2-AS1 expression was firstly detected in the gastric carcinoma tissue samples as well as in gastric cancer cells. Knockdown of ZEB2-AS1 was performed by ZEB2-AS1-shRNA, and the viability, migration, invasion, and apoptosis of gastric cancer cells were determined by CCK-8, scratch assay, transwell, and flow cytometry, respectively. Furthermore, levels of Ki-67, PCNA, VEGF, MMP9, epithelial-mesenchymal transition (EMT) markers (E-cadherin, Vimentin and ZEB2), cleaved caspase 3/8/9 and PARP, active β-catenin, c-Myc, cyclinD1, and AXIN2 were assayed by Western blot or real-time PCR. Additionally, the role and mechanism of ZEB2-AS1 were confirmed in a xenograft nude mouse model. We found ZEB2-AS1 expression was increased in gastric carcinoma samples, and it was correlated with tumor progression. Also, its expression was elevated in gastric cancer cells. Knockdown of ZEB2-AS1 reduced the proliferation, migration, invasion, and EMT, but increased the apoptosis of gastric carcinoma cells. Furthermore, ZEB2-AS1 downregulation remarkably suppressed the expression of Ki-67, PCNA, VEGF and MMP9, and the activation of Wnt/β-catenin signaling, whereas elevated the levels of cleaved caspase 3/8/9 and PARP in gastric cancer cells. And ZEB2 overexpression reversed the effects of ZEB2-AS1 downregulation on the proliferation, EMT and inactivation of Wnt/β-catenin signaling. Additionally, ZEB2-AS1 knockdown inhibited tumor growth, Ki-67 staining, and the expression of VEGF, MMP9, active β-catenin, c-Myc, cyclinD1, and AXIN2 in mice. In conclusion, ZEB2-AS1 promotes the tumorigenesis of gastric carcinoma that is related to the upregulation of ZEB2 and the activation of the Wnt/β-catenin pathway.

Indexed as

Down-RegulationGene Expression Regulation, NeoplasticWnt Signaling Pathwaybeta CateninCell Line, TumorHumansNeoplasm ProteinsRNA, Long NoncodingRNA, NeoplasmStomach Neoplasmsbeta CateninNeoplasm ProteinsRNA, Long NoncodingRNA, NeoplasmGastric cancerLong noncoding RNAsWnt/β-cateninZEB2ZEB2-AS1

Identifiers

PMID30635820
OpenAlexW2909185428

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.